United Therapeutics Corp

Discover why United Therapeutics’ leadership is buying and selling shares at strategic times—insider moves reveal confidence in a growing vascular therapy pipeline and solid long‑term upside.

Explore United Therapeutics’ insider trades: Paul Mahon’s 8,300‑share buy and strategic option sales reveal strong management alignment and a modest upside potential for UTHR investors.

United Therapeutics insider activity: CEO Benkowitz’s recent purchase signals long‑term confidence and potential upside for UTHR’s biotech pipeline.

Malcolm Jan’s recent 50‑share sale at United Therapeutics is a routine portfolio move, not a bearish signal—watch upcoming earnings for any shift.

Insightful UTHR insider trade recap: Paul Mahon’s February 2026 10(b)(5)(1) option exercise shows routine liquidity, not a warning. Read why it matters.

United Therapeutics insider Benkowitz buys 14,625 shares under a Rule 10b5‑1 plan—steady, plan‑driven buying that signals long‑term confidence in the company’s pulmonary‑hypertension pipeline.

Malcolm Jan’s regular 10‑billion‑plan sales at United Therapeutics show steady portfolio rebalancing, not a bearish signal—focus on the company’s strong pipeline and solid valuation.

United Therapeutics insider sale: Paul Mahon’s 10(b)(5)(1) option exercise reveals a routine, plan‑driven liquidity move—no immediate risk but worth monitoring for future shifts.

Insightful look at United Therapeutics’ insider trade – Michael Benkowitz’s 10b5‑1 option sale shows routine liquidity management, not a red flag.

United Therapeutics insider trades: CEO Benkowitz’s bulk Rule‑10b5‑1 sales and a single purchase reveal liquidity moves, not a confidence shift, while UTHR’s steady pipeline and rising price suggest bullish fundamentals.